Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

In patients with psoriasis or ankylosing spondylitis, the use of interleukin (IL)-17A inhibitors, particularly secukinumab, was associated with an increased risk for inflammatory bowel disease ...